Gyn-Onc
Advertisement
Uterine carcinosarcoma is responsible for more than 16% of all deaths caused by uterine malignancy, despite its rarity.
Uterine cancer, including endometrial carcinoma, is a major public health concern in the EU.
The findings were presented as an abstract during the American Society of Clinical Oncology 2025 Annual Meeting.
Learn about the impact of an interactive education program on cervical cancer prevention perceptions in Northwest Nigeria.
Nurse Practitioner Scientist shares insights from her research on how nurses can help reduce cervical cancer stigma.
Ortiz discussed why realizing the widespread prevalence of trauma is critical in providing trauma-informed care to patients.
Learn why patients with ovarian cancer disengage with online symptom management interventions over time.
Learn how income, education, and other neighborhood deprivation factors correlate with gynecologic cancer symptom burden.
The investigators highlighted that uptake of the HPV vaccine remains suboptimal within certain patient populations.
It's critical for oncology nurses to ask patients certain questions about their morning and evening fatigue levels.
Learn about the role of psychological resilience in dyadic coping and adjustment for couples facing cervical cancer.
The study found that patients with cervical cancer may be at risk for malnutrition if treated with chemoradiotherapy.
Research on follow-up adherence in patients with cervical cancer shows how nurse liaisons can help reduce patient anxiety.
The study explores the effects of a Saturday pap smear clinic on improving access to cervical cancer screening for women.
Socioeconomic barriers and access to palliative chemotherapy affect survival outcomes for patients with cervical cancer.
Women with deep infiltrating endometriosis and/or ovarian endometriosis had the highest risk for ovarian cancer.
Learn how a team implemented pre-screening and fast-track strategies to increase clinical trial enrollment in these patients.
New research highlights the importance of using appropriate patient-reported outcome measures for these patients.
The phase III, placebo-controlled AtTEnd trial included 551 patients, with 23% in each arm having dMMR tumors.
Symptom-triggered testing resulted in 1 in 4 women being diagnosed with high-grade serous ovarian cancer at an early stage.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.